MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/ana.21743

Медицинская библиотека · Annals of neurology · 2009

Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III.

Kaufmann Petra, Thompson John L P, Levy Gilberto, Buchsbaum Richard, Shefner Jeremy, Krivickas Lisa S, Katz Jonathan, Rollins Yvonne, Barohn Richard J, Jackson Carlayne E, Tiryaki Ezgi, Lomen-Hoerth Catherine, Armon Carmel, Tandan Rup, Rudnicki Stacy A, Rezania Kourosh, Sufit Robert, Pestronk Alan, Novella Steven P, Heiman-Patterson Terry, Kasarskis Edward J, Pioro Erik P, Montes Jacqueline, Arbing Rachel, Vecchio Darleen, Barsdorf Alexandra, Mitsumoto Hiroshi, Levin Bruce, QALS Study Group

Клиническое исследование II фазыСтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка NIH: внешняя программаПеревод в очереди

Аннотация

OBJECTIVE

Amyotrophic lateral sclerosis (ALS) is a devastating, and currently incurable, neuromuscular disease in which oxidative stress and mitochondrial impairment are contributing to neuronal loss. Coenzyme Q10 (CoQ10), an antioxidant and mitochondrial cofactor, has shown promise in ALS transgenic mice, and in clinical trials for neurodegenerative diseases other than ALS. Our aims were to choose between two high doses of CoQ10 for ALS, and to determine if it merits testing in a Phase III clinical trial.

METHODS

We designed and implemented a multicenter trial with an adaptive, two-stage, bias-adjusted, randomized, placebo-controlled, double-blind, Phase II design (n = 185). The primary outcome in both stages was a decline in the ALS Functional Rating Scale-revised (ALSFRSr) score over 9 months. Stage 1 (dose selection, 35 participants per group) compared CoQ10 doses of 1,800 and 2,700 mg/day. Stage 2 (futility test, 75 patients per group) compared the dose selected in Stage 1 against placebo.

RESULTS

Stage 1 selected the 2,700 mg dose. In Stage 2, the pre-specified primary null hypothesis that this dose is superior to placebo was not rejected. It was rejected, however, in an accompanying prespecified sensitivity test, and further supplementary analyses. Prespecified secondary analyses showed no significant differences between CoQ10 at 2,700 mg/day and placebo. There were no safety concerns.

INTERPRETATION: CoQ10 at 2,700 mg daily for 9 months shows insufficient promise to warrant Phase III testing. Given this outcome, the adaptive Phase II design incorporating a dose selection and a futility test avoided the need for a much larger conventional Phase III trial.

Для цитирования: Kaufmann Petra, Thompson John L P, Levy Gilberto, Buchsbaum Richard, Shefner Jeremy, Krivickas Lisa S, Katz Jonathan, Rollins Yvonne, Barohn Richard J, Jackson Carlayne E, Tiryaki Ezgi, Lomen-Hoerth Catherine, Armon Carmel, Tandan Rup, Rudnicki Stacy A, Rezania Kourosh, Sufit Robert, Pestronk Alan, Novella Steven P, Heiman-Patterson Terry, Kasarskis Edward J, Pioro Erik P, Montes Jacqueline, Arbing Rachel, Vecchio Darleen, Barsdorf Alexandra, Mitsumoto Hiroshi, Levin Bruce, QALS Study Group. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III.. Annals of neurology. 2009. DOI: 10.1002/ana.21743.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.